Myhep Lvir

  • Medicine Name: Myhep Lvir
  • API: Sofosbuvir+Ledipasvir
  • Strength: Ledipasvir (90mg) + Sofosbuvir (400mg)
  • Pack Size: 28 tablets bottle
  • Marketed by: Mylan Pharmaceuticals Pvt Ltd
Get an Enquiry
Category:

Description

Myhep Lvir tablet is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. 

Dosage and Side Effects

  • Recommended dosage: One Sofosbuvir and Ledipasvir tablet taken orally once daily with or without food.
  • Recommended treatment duration: 
    • Treatment-naïve with or without cirrhosis: 12 weeks 
    • Treatment-experienced without cirrhosis: 12 weeks 
    • Treatment-experienced with cirrhosis: 24 weeks
  •  A dose recommendation cannot be made for patients with severe renal impairment or end stage renal disease.

The most common side-effects observed with treatment with Sofosbuvir and Ledipasvir  for 8, 12, or 24 weeks are fatigue and headache.

Warning and Precautions

Use with other drugs containing sofosbuvir, including SOVALDI, is not recommended.

FAQ's

What is the use of Sofosbuvir and Ledipasvir?

The combination medicine Sofosbuvir and Ledipasvir is recommended to treat chronic hepatitis C (CHC) genotype 1 infection.

When was Ledipasvir and Sofosbuvir approved by the FDA?

The FDA approved the combination medicine Sofosbuvir and Ledipasvir in 2014.

What drug class is Sofosbuvir and Ledipasvir?

Sofosbuvir and Ledipasvir combination comes under the class of nucleotide polymerase inhibitors.